Orca-T improves Chronic Graph-versus-Host Disease Free in Patients with a Broad Range of Demographic and Clinical Variables: Results of Randomized, Phase 3 Trial

BackgroundOrca-T is an allogeneic T-cell immunotherapy using purified donor regulatory T cells to prevent graft-versus-host disease (GVHD).The randomized Ph3 Precision-T trial (NCT05316701) showed improved moderate-tosevere chronic GVHD-free survival with Orca-T versus standard-of-care transplantation with tacrolimus+methotrexate prophylaxis.This analysis examines outcomes in prespecified patient subgroups from Precision-T.